Overview
B Riley Securities reiterated its buy rating on The Oncology Institute (TOI) with an $8 price target, designating the stock as the best idea presented at its May conference. The firm highlighted that TOI has eliminated a near‑term financing overhang by refinancing its $86 million convertible debt due in August 2027. The refinancing was executed by repaying the outstanding balance using a $75 million term loan provided by OrbiMed and $11 million drawn from the company’s cash balance, completing the transaction without any additional equity issuance.
The new $75 million term loan carries a maturity date in 2031 and an anticipated interest rate range of 9 % to 12 %. B Riley analysts Yuan Zhi and Liwen Wang noted that TOI’s free cash flow improved by $20 million at the midpoint of its 2026 guidance, which supported the successful refinancing.
Financial Guidance
B Riley projects that TOI will generate revenue of $152.8 million in the second quarter of 2026, which is slightly below the consensus estimate of $155.2 million. Adjusted EBITDA for the same quarter is expected to range from a negative $1 million to a positive $1 million, reflecting seasonal improvement following deductible resets and continued ramp‑up of operations in Florida. Management reiterated its expectation of 20 % annual revenue growth over the next few years, targeting $1 billion in revenue by 2028 together with adjusted EBITDA in the range of $50 million to $60 million.
Analyst Updates
In addition to B Riley’s reaffirmation, other sell‑side analysts issued updated coverage: Lake Street initiated coverage with a Buy rating and a $10 price target, BTIG raised its price target to $9, and Needham increased its target to $7.